Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib

被引：0
|
作者：
Kazuo Tamura
Toshihiro Nukiwa
Akihiko Gemma
Nobuyuki Yamamoto
Masaya Mizushima
Kaori Ochai
Rie Ikeda
Hisaya Azuma
Yoichi Nakanishi
机构：
[1] Fukuoka University,General Medical Research Center, School of Medicine
[2] Tohoku University,Division of Pulmonology and Medical Oncology, Third Department of Internal Medicine
[3] Nippon Medical School,Speciality Care Medicine, Medical Division
[4] Wakayama Medical University,PMS Division, Statistics Analysis Department 2
[5] Nippon Boehringer Ingelheim Co.,Post Marketing Surveillance Group, Pharmacovigilance
[6] Ltd.,Research Institute for Diseases of the Chest, Graduate School of Medical Sciences
[7] EPS Corporation,undefined
[8] Nippon Boehringer Ingelheim Co.,undefined
[9] Ltd.,undefined
[10] Kyusyu University,undefined
来源：
International Journal of Clinical Oncology | 2019年 / 24卷
关键词：
Afatinib; m + NSCLC; Japanese patients; Real-world data; Post-marketing observational study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：917 / 926
页数：9
相关论文
共 50 条
  • [1] Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
    Tamura, Kazuo
    Nukiwa, Toshihiro
    Gemma, Akihiko
    Yamamoto, Nobuyuki
    Mizushima, Masaya
    Ochai, Kaori
    Ikeda, Rie
    Azuma, Hisaya
    Nakanishi, Yoichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (08) : 917 - 926
  • [2] Correction to: Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
    Kazuo Tamura
    Toshihiro Nukiwa
    Akihiko Gemma
    Nobuyuki Yamamoto
    Masaya Mizushima
    Kaori Ochai
    Rie Ikeda
    Hisaya Azuma
    Yoichi Nakanishi
    International Journal of Clinical Oncology, 2019, 24 : 1169 - 1169
  • [3] Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib (vol 24, pg 917, 2019)
    Tamura, Kazuo
    Nukiwa, Toshihiro
    Gemma, Akihiko
    Yamamoto, Nobuyuki
    Mizushima, Masaya
    Ochai, Kaori
    Ikeda, Rie
    Azuma, Hisaya
    Nakanishi, Yoichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (09) : 1169 - 1169
  • [4] Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?
    Watanabe, Satomi
    Hayashi, Hidetoshi
    Nakagawa, Kazuhiko
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (11)
  • [5] Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
    Satoshi Igawa
    Taihei Ono
    Masashi Kasajima
    Seiichiro Kusuhara
    Sakiko Otani
    Tomoya Fukui
    Masanori Yokoba
    Masaru Kubota
    Masato Katagiri
    Hisashi Mitsufuji
    Jiichiro Sasaki
    Katsuhiko Naoki
    Investigational New Drugs, 2020, 38 : 1906 - 1914
  • [6] Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
    Igawa, Satoshi
    Ono, Taihei
    Kasajima, Masashi
    Kusuhara, Seiichiro
    Otani, Sakiko
    Fukui, Tomoya
    Yokoba, Masanori
    Kubota, Masaru
    Katagiri, Masato
    Mitsufuji, Hisashi
    Sasaki, Jiichiro
    Naoki, Katsuhiko
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1906 - 1914
  • [7] Impact of afatinib dosing on safety and efficacy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) in a real-world setting
    Halmos, Balazs
    Tan, Eng-Huat
    Soo, Ross
    Cadranel, Jacques
    Lee, Min Ki
    Foucher, Pascal
    Hsia, Te-Chun
    Hochmair, Maximilian
    Griesinger, Frank
    Hida, Toyoaki
    Kim, Edward
    Melosky, Barbara
    Maerten, Angela
    Carcereny, Enric
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 160 - 161
  • [8] Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
    Lee, Sung Yong
    Choi, Chang-Min
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Ji Young
    Kim, Young-Chul
    Oh, In-Jae
    Jung, Chi Young
    Lee, Sang Hoon
    Yoon, Seong Hoon
    Choi, Juwhan
    Jang, Tae Won
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (12) : 4353 - +
  • [9] First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
    Park, Keunchil
    Lim, Darren Wan-Teck
    Okamoto, Isamu
    Yang, James Chih-Hsin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [10] Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer
    Alsharedi, M.
    Bukamur, H.
    Elhamdani, A.
    DRUGS OF TODAY, 2018, 54 (06) : 369 - 379
12345